TNFRSF7/CD27 Extracellular Domain (human, recombinant)

CD27, also known as tumor necrosis factor receptor superfamily receptor 7 (TNFRSF7), is a type I transmembrane glycoprotein with roles in T cell-mediated immunity.^1,2 It is comprised of an extracellular domain containing three cysteine-rich domains (CRDs), a transmembrane domain, and a short cytoplasmic domain that facilitates intracellular signaling.¹ CD27 is expressed on a broad range of lymphocytes, including natural killer (NK), B, and T cells, with T cell CD27 expression increasing upon T cell receptor stimulation.³ Binding of homotrimeric CD70 to CD27 on antigen-primed T cells induces NF-kB and MAPK signaling through TNF receptor-associated factors (TRAFs) and, when the T cell is stimulated by other factors, induces PI3K signaling to induce the co-stimulation and expansion of naïve CD4⁺ and CD8⁺ T cells.^4,5 Knockout of CD27 reduces thymic development of regulatory T cell (Treg) precursors and enhances apoptosis of mature Tregs in mice. Levels of CD27-expressing plasma cells are increased in the periphery and positively correlate with the disease activity index and serum levels of anti-dsDNA autoantibodies in patients with systemic lupus erythematosus (SLE).⁶ Cayman’s TNFRSF7/CD27 Extracellular Domain (human, recombinant) protein can be used for binding assay applications. This protein is a disulfide-linked homodimer. The reduced monomer, comprised of CD27 (amino acids 21-192) fused to His-tagged human IgG1 Fc at its C-terminus, consists of 420 amino acids, has a calculated molecular weight of 47.2 kDa, and a predicted N-terminus of Thr21 after signal peptide cleavage. As a result of glycosylation, the monomer migrates at approximately 65 kDa by SDS-PAGE under reducing conditions.

WARNING This product is not for human or veterinary use.

1. Buchan, S.L., Rogel, A., and Al-Shamkhani, A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood 131(1), 39-48 (2018).

2. Grant, E.J., Nüssing, S., Sant, S., et al. The role of CD27 in anti-viral T-cell immunity. Curr. Opin. Virol. 22, 77-88 (2017).

3. Hendriks, J., Gravestein, L.A., Tesselaar, K., et al. CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 1(5), 433-440 (2000).

4. Wyzgol, A., Müller, N., Fick, A., et al. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J. Immunol. 183(3), 1851-1861 (2009).

5. Wajant, H. Therapeutic targeting of CD70 and CD27. Expert Opin. Ther. Targets 20(8), 959-973 (2016).

6. Han, B.K., Olsen, N.J., and Bottaro, A. The CD27-CD70 pathway and pathogenesis of autoimmune disease. Semin. Arthritis Rheum. 45(4), 496-501 (2016).